Efexor XL licence extended

Efexor XL (venlafaxine) is now indicated in moderate to severe generalised social anxiety disorder/social phobia in adults.

Efexor is also indicated in major depressive disorder and in moderate to severe generalised anxiety disorder. The recommended dose in social anxiety disorder is 75mg once daily.

If the patient has failed to respond after 12 weeks, alternative therapy should be considered. Continuation of treatment in a responding patient can be considered on an individual basis, but there is no evidence of efficacy beyond six months.

 

Further information: Wyeth 0845 3670098

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...